Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.1K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

400
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
400
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.0K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.0K
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

726
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
726
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

520
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
520

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trientine for hypertrophic cardiomyopathy: a phase 2 trial.

European heart journal·2026
Same author

Gut microbe-generated metabolite trimethylamine N-oxide and risk of abdominal aortic aneurysm: a cohort study.

European heart journal·2026
Same author

Non-invasive pressure-volume loop analysis in left ventricular load manipulation.

Clinical physiology and functional imaging·2026
Same author

Interleukin-17A mediates cardiorenal injury in oxalate nephropathy.

Cardiovascular research·2026
Same author

A systematic review of explainable artificial intelligence and cardiac electrophysiological models addressing sports-related sudden cardiac death and arrest in adolescents and young adults.

NPJ digital medicine·2026
Same author

Multidisciplinary approach to implementing ferric carboxymaltose for IV iron replacement in heart failure with iron deficiency.

Future cardiology·2026

Related Experiment Video

Updated: Feb 26, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

HFpEF and MASLD: converging mechanisms and clinical implications.

Federico Capone1,2,3,4,5, Steffen P Häseli1,2, Luo Liu1,2

  • 1Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Max Rubner Center for Cardiovascular Metabolic Renal Research (MRC), Charité-Universitätsmedizin Berlin, Berlin, Germany.

Nature Reviews. Cardiology
|February 24, 2026
PubMed
Summary

Heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatotic liver disease (MASLD) are linked by shared metabolic issues. Understanding the liver-heart axis is crucial for managing these interconnected conditions.

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K

Related Experiment Videos

Last Updated: Feb 26, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K

Area of Science:

  • Cardiology
  • Hepatology
  • Metabolic Diseases

Background:

  • Heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatotic liver disease (MASLD) are rising globally, linked to obesity and metabolic syndrome.
  • These conditions were previously studied separately but are now understood as linked manifestations of systemic metabolic dysfunction.
  • Recent evidence highlights shared risk factors and a bidirectional communication pathway between the liver and heart.

Purpose of the Study:

  • To explore the epidemiological and mechanistic links between MASLD and HFpEF.
  • To examine shared metabolic drivers like lipotoxicity, meta-inflammation, and oxidative stress.
  • To discuss liver-derived mediators affecting cardiac function and propose integrated management strategies.

Main Methods:

  • Review of epidemiological data and mechanistic studies on the MASLD-HFpEF connection.
  • Analysis of shared metabolic pathways including lipotoxicity, meta-inflammation, and oxidative stress.
  • Examination of emerging liver-derived mediators (hepatokines, metabolites, extracellular vesicles) impacting the heart.

Main Results:

  • MASLD and HFpEF share common metabolic drivers and risk factors.
  • A dynamic, bidirectional crosstalk exists between the liver and heart.
  • Liver-derived factors significantly influence cardiac structure and function.

Conclusions:

  • The liver-heart axis is central to understanding the interplay between MASLD and HFpEF.
  • Integrated, multiorgan approaches are needed for clinical recognition and management.
  • Rethinking cardiometabolic disease beyond organ-specific silos is essential for improved patient outcomes.